Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510871 | 0.87 | EPHX1 (0.44) | PPARGPPARASLC6A2SLC6A4MAOA | |
| SCHEMBL10899765 | 0.85 | L3MBTL1 (0.47) | PPARGPPARATAAR1SLC6A2SLC6A4 | |
| SCHEMBL7215558 | 0.81 | PPARG (0.42) | PPARGPPARATAAR1SLC6A2SLC6A4 | |
| SCHEMBL1467047 | 0.81 | SLC6A2 (0.52) | PPARGPPARATAAR1SLC6A2SLC6A4 | |
| SCHEMBL4850434 | 0.81 | PPARG (0.42) | PPARGPPARATAAR1SLC6A2SLC6A4 | |
| SCHEMBL24013069 | 0.81 | IDO1 (0.43) | PPARGPPARATAAR1SLC6A2SLC6A4 | |
| SCHEMBL10585977 | 0.81 | NPSR1 (0.47) | PPARGPPARASLC6A4L3MBTL1ATM | |
| Hydrochloric Acid SCHEMBL1466263 | 0.79 | SLC6A2 (0.50) | PPARGPPARATAAR1SLC6A2SLC6A4 | |
| SCHEMBL2878611 | 0.79 | L3MBTL1 (0.42) | PPARGPPARATAAR1SLC6A2SLC6A4 | |
| SCHEMBL17251292 | 0.79 | L3MBTL1 (0.42) | PPARGPPARATAAR1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115651017-B | Method for selectively preparing benzyl or alkyl phosphine oxide compound based on benzyl thioether derivative | 中南大学 | 2025-05-27 | — | — | CN | claimed |
| CN-115651017-A | Method for selectively preparing benzyl or alkyl phosphine oxide compound based on benzyl thioether derivative | 中南大学 | 2023-01-31 | — | — | CN | claimed |
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | claimed |
| EP-2864318-B1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1R KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2017-08-09 | — | — | EP | claimed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | claimed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | claimed |
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | claimed |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-05-07 | — | — | US | claimed |
| US-8962825-B2 | Hydroxamates as inhibitors of histone deacetylase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-02-24 | — | — | US | claimed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | claimed |
| EP-0763012-A1 | SUCCINYL HYDROXAMIC ACID, N-FORMYL-N-HYDROXY AMINO CARBOXYLIC ACID AND SUCCINIC ACID AMIDE DERIVATIVES AS METALLOPROTEASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-03-19 | — | — | EP | claimed |
| WO-1997003783-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-02-06 | — | — | WO | claimed |
| EP-0740652-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | claimed |
| EP-0740655-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | claimed |
| WO-1996033161-A1 | DERIVATIVES OF SUCCINAMIDE AND THEIR USE AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-10-24 | — | — | WO | claimed |
| WO-1996033165-A1 | DERIVATIVES OF SUCCINAMIDE AND THEIR USE AS METALLOPROTEINASE INHIBITOR | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-10-24 | — | — | WO | claimed |
| WO-1995035275-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-12-28 | — | — | WO | claimed |
| WO-1995032944-A1 | SUCCINYL HYDROXAMIC ACID, N-FORMYL-N-HYDROXY AMINO CARBOXYLIC ACID AND SUCCINIC ACID AMIDE DERIVATIVES AS METALLOPROTEASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-12-07 | — | — | WO | claimed |
| WO-1995019956-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | claimed |
| WO-1995019961-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137594-A1 | HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | PPARG 711/4885PPARA 966/4885TAAR1 2541/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | PPARG 2441/4885PPARA 2014/4885TAAR1 1761/4885 |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | PPARG 1482/4885PPARA 1422/4885TAAR1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.